Brief: Fate Therapeutics Inc - On May 30, Edward J. Dulac Iii Provided Notice Of His Resignation From His Position As Chief Financial Officer
31/05/2024 22:39
Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS INC - ON MAY 30, EDWARD J. DULAC III
PROVIDED
NOTICE OF HIS RESIGNATION FROM HIS POSITION AS CHIEF FINANCIAL
OFFICER
* FATE THERAPEUTICS INC - BOARD INTENDS TO APPOINT J. SCOTT
WOLCHKO TO SUCCEED DULAC AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:n0001193125-24-151963
Further company coverage: FATE.O
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview